$RVNC
Revance Therapeutics, Inc. Stock $rvnc

$rvnc Overview Financials Valuation SEC Filings Company Website

2015 Q2 Form 10-Q Financial Statement

#000162828015006314 Filed on August 07, 2015

Income Statement

Concept	2015 Q2	2014 Q2	2012
Revenue	$75.00K	$75.00K	$150.0K
YoY Change	0.0%	0.0%	-73.21%
Cost Of Revenue			$0.00
YoY Change			-100.0%
Gross Profit			$720.0K
YoY Change			30.91%
Gross Profit Margin			480.0%
Selling, General & Admin	$6.360M	$4.857M	$12.36M
YoY Change	30.95%	33.4%	122.23%
% of Gross Profit			1716.11%
Research & Development	$10.30M	$8.110M	$19.56M
YoY Change	27.04%	4.21%	-14.0%
% of Gross Profit			2716.25%
Depreciation & Amortization	$550.0K	$500.0K	$1.777M
YoY Change	10.0%	25.0%	-10.25%
% of Gross Profit			246.81%
Operating Expenses	$16.66M	$12.97M	$31.91M
YoY Change	28.5%	13.52%	12.81%
Operating Profit	-$16.59M	-$12.89M	-$31.76M
YoY Change	28.67%	13.61%	14.5%
Interest Expense	$279.0K	$267.0K	$444.0K
YoY Change	4.49%	-45.51%	-102.57%
% of Operating Profit
Other Income/Expense, Net	-$76.00K	-$68.00K	-$123.0K
YoY Change	11.76%	1600.0%	-172.35%
Pretax Income	-$16.81M	-$13.30M	-$58.26M
YoY Change	26.39%	12.43%	29.87%
Income Tax		$0.00	$0.00
% Of Pretax Income
Net Earnings	-$16.81M	-$13.30M	-$32.21M
YoY Change	26.33%	12.45%	-28.21%
Net Earnings / Revenue	-22406.67%	-17736.0%	-21471.33%
Basic Earnings Per Share	-$0.71	-$0.69	-$1.37
Diluted Earnings Per Share	-$0.71	-$0.69	-$1.37
COMMON SHARES
Basic Shares Outstanding	23.58M shares	19.38M shares	23.56M shares
Diluted Shares Outstanding	23.58M shares	19.38M shares	23.56M shares

Balance Sheet

Concept	2015 Q2	2014 Q2	2012
SHORT-TERM ASSETS
Cash & Short-Term Investments	$135.3M	$203.3M	$4.100M
YoY Change	-33.45%		-86.15%
Cash & Equivalents	$96.42M	$203.3M	$4.100M
Short-Term Investments	$38.90M
Other Short-Term Assets	$1.900M	$134.0K	$1.300M
YoY Change	1317.91%		160.0%
Inventory
Prepaid Expenses		$1.462M
Receivables		$188.0K	$100.0K
Other Receivables		$0.00	$0.00
Total Short-Term Assets	$137.3M	$206.6M	$5.400M
YoY Change	-33.55%		-82.06%
LONG-TERM ASSETS
Property, Plant & Equipment	$19.13M	$16.32M	$7.000M
YoY Change	17.21%		-16.67%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$14.10M
YoY Change
Other Assets	$374.0K		$1.000M
YoY Change			-28.57%
Total Long-Term Assets	$33.96M	$16.76M	$8.000M
YoY Change	102.64%		-18.37%
TOTAL ASSETS
Total Short-Term Assets	$137.3M	$206.6M	$5.400M
Total Long-Term Assets	$33.96M	$16.76M	$8.000M
Total Assets	$171.2M	$223.3M	$13.40M
YoY Change	-23.33%		-66.42%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.211M	$2.687M	$1.800M
YoY Change	-17.71%		125.0%
Accrued Expenses	$5.040M	$5.033M	$5.600M
YoY Change	0.14%		107.41%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$2.900M	$11.00M	$95.40M
YoY Change	-73.64%		1973.91%
Total Short-Term Liabilities	$10.16M	$18.77M	$117.9M
YoY Change	-45.87%		1224.72%
LONG-TERM LIABILITIES
Long-Term Debt	$7.000M	$700.0K	$11.40M
YoY Change	900.0%		-82.43%
Other Long-Term Liabilities	$5.200M	$5.300M	$5.400M
YoY Change	-1.89%		-79.39%
Total Long-Term Liabilities	$12.20M	$6.000M	$16.80M
YoY Change	103.33%		-81.56%
TOTAL LIABILITIES
Total Short-Term Liabilities	$10.16M	$18.77M	$117.9M
Total Long-Term Liabilities	$12.20M	$6.000M	$16.80M
Total Liabilities	$22.38M	$24.81M	$134.7M
YoY Change	-9.81%		34.7%
SHAREHOLDERS EQUITY
Retained Earnings	-$291.0M	-$230.6M
YoY Change	26.19%
Common Stock	$439.9M	$429.1M
YoY Change	2.5%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$148.8M	$198.5M	-$121.3M
YoY Change
Total Liabilities & Shareholders Equity	$171.2M	$223.3M	$13.40M
YoY Change	-23.33%		-66.42%

Cashflow Statement

Concept	2015 Q2	2014 Q2	2012
OPERATING ACTIVITIES
Net Income	-$16.81M	-$13.30M	-$32.21M
YoY Change	26.33%	12.45%	-28.21%
Depreciation, Depletion And Amortization	$550.0K	$500.0K	$1.777M
YoY Change	10.0%	25.0%	-10.25%
Cash From Operating Activities	-$12.48M	-$12.15M	-$38.91M
YoY Change	2.72%	-41.39%	36.97%
INVESTING ACTIVITIES
Capital Expenditures	-$490.0K	-$2.430M	$319.0K
YoY Change	-79.84%	22.11%	-312.67%
Acquisitions
YoY Change
Other Investing Activities	-$53.08M	$0.00	$80.00K
YoY Change			0.0%
Cash From Investing Activities	-$53.56M	-$2.430M	-$244.0K
YoY Change	2104.12%	22.11%	205.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	8.750M	130.0M	$13.62M
YoY Change	-93.27%	1832.24%	-74.81%
NET CHANGE
Cash From Operating Activities	-12.48M	-12.15M	-$38.91M
Cash From Investing Activities	-53.56M	-2.430M	-$244.0K
Cash From Financing Activities	8.750M	130.0M	$13.62M
Net Change In Cash	-57.29M	115.5M	-$25.54M
YoY Change	-149.62%	-822.08%	-199.84%
FREE CASH FLOW
Cash From Operating Activities	-$12.48M	-$12.15M	-$38.91M
Capital Expenditures	-$490.0K	-$2.430M	$319.0K
Free Cash Flow	-$11.99M	-$9.720M	-$39.23M
YoY Change	23.35%	-48.13%	38.83%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
CY2015Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	23950519	shares
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Period End Date DocumentPeriodEndDate	2015-06-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001479290
	dei	Entity Incorporation Date Of Incorporation EntityIncorporationDateOfIncorporation	1999-08-10
	dei	Entity Information Date To Change Former Legal Or Registered Name EntityInformationDateToChangeFormerLegalOrRegisteredName	2005-04-19
	dei	Entity Registrant Name EntityRegistrantName	Revance Therapeutics, Inc.
	rvnc	Accrualfor Reimbursable Tenant Improvements AccrualforReimbursableTenantImprovements	1109000	USD
	rvnc	Accrualfor Reimbursable Tenant Improvements AccrualforReimbursableTenantImprovements	0	USD
CY2015Q2	rvnc	Cash Cash Equivalentsand Investments CashCashEquivalentsandInvestments	149400000	USD
	rvnc	Cashand Cash Equivalentsand Investments Operating Plan Funding Term Minimum CashandCashEquivalentsandInvestmentsOperatingPlanFundingTermMinimum	P12M
CY2012	rvnc	Changein Fair Valueof Convertible Preferred Stock Warrant ChangeinFairValueofConvertiblePreferredStockWarrant	0	USD
CY2014Q2	rvnc	Changein Fair Valueof Convertible Preferred Stock Warrant ChangeinFairValueofConvertiblePreferredStockWarrant	0	USD
	rvnc	Changein Fair Valueof Convertible Preferred Stock Warrant ChangeinFairValueofConvertiblePreferredStockWarrant	-210000	USD
CY2015Q2	rvnc	Changein Fair Valueof Convertible Preferred Stock Warrant ChangeinFairValueofConvertiblePreferredStockWarrant	0	USD
	rvnc	Conversion Of Preferred Stock Warrants To Common Stock Warrants ConversionOfPreferredStockWarrantsToCommonStockWarrants	1441000	USD
	rvnc	Conversion Of Preferred Stock Warrants To Common Stock Warrants ConversionOfPreferredStockWarrantsToCommonStockWarrants	0	USD
	rvnc	Extinguishmentof Warrant Liability Upon Exerciseof Put Option ExtinguishmentofWarrantLiabilityUponExerciseofPutOption	1356000	USD
	rvnc	Extinguishmentof Warrant Liability Upon Exerciseof Put Option ExtinguishmentofWarrantLiabilityUponExerciseofPutOption	0	USD
CY2014Q4	rvnc	Financing Lease Obligation Noncurrent Netof Current Portion FinancingLeaseObligationNoncurrentNetofCurrentPortion	598000	USD
CY2015Q2	rvnc	Financing Lease Obligation Noncurrent Netof Current Portion FinancingLeaseObligationNoncurrentNetofCurrentPortion	6973000	USD
CY2014Q4	rvnc	Financing Obligation Current FinancingObligationCurrent	307000	USD
CY2015Q2	rvnc	Financing Obligation Current FinancingObligationCurrent	2906000	USD
CY2015Q2	rvnc	Financing Obligation Future Minimum Payments Due FinancingObligationFutureMinimumPaymentsDue	11246000	USD
CY2015Q2	rvnc	Financing Obligation Future Minimum Payments Duein Four Years FinancingObligationFutureMinimumPaymentsDueinFourYears	949000	USD
CY2015Q2	rvnc	Financing Obligation Future Minimum Payments Duein Three Years FinancingObligationFutureMinimumPaymentsDueinThreeYears	3971000	USD
CY2015Q2	rvnc	Financing Obligation Future Minimum Payments Duein Two Years FinancingObligationFutureMinimumPaymentsDueinTwoYears	4217000	USD
CY2015Q2	rvnc	Financing Obligation Future Minimum Payments Next Twelve Months FinancingObligationFutureMinimumPaymentsNextTwelveMonths	2109000	USD
CY2012	rvnc	Gain Loss On Settlement In Exchange Of Preferred Stock Warrants GainLossOnSettlementInExchangeOfPreferredStockWarrants	0	USD
CY2014Q2	rvnc	Gain Loss On Settlement In Exchange Of Preferred Stock Warrants GainLossOnSettlementInExchangeOfPreferredStockWarrants	0	USD
	rvnc	Gain Loss On Settlement In Exchange Of Preferred Stock Warrants GainLossOnSettlementInExchangeOfPreferredStockWarrants	-1356000	USD
	rvnc	Issuance Of Common Stock Warrants IssuanceOfCommonStockWarrants	981000	USD
	rvnc	Issuance Of Common Stock Warrants IssuanceOfCommonStockWarrants	0	USD
	rvnc	Issuance Of Convertible Preferred Stock Warrants IssuanceOfConvertiblePreferredStockWarrants	80000	USD
	rvnc	Issuance Of Convertible Preferred Stock Warrants IssuanceOfConvertiblePreferredStockWarrants	0	USD
	rvnc	Interest Expense Warrantand Derivative Related Debt Discounts InterestExpenseWarrantandDerivativeRelatedDebtDiscounts	142000	USD
CY2015Q2	rvnc	Interest Expense Warrantand Derivative Related Debt Discounts InterestExpenseWarrantandDerivativeRelatedDebtDiscounts	0	USD
	rvnc	Interest Expense Warrantand Derivative Related Debt Discounts InterestExpenseWarrantandDerivativeRelatedDebtDiscounts	5000	USD
	rvnc	Issuance Of Common Stock Upon Net Exercise Of Warrants IssuanceOfCommonStockUponNetExerciseOfWarrants	6490000	USD
	rvnc	Issuance Of Common Stock Upon Net Exercise Of Warrants IssuanceOfCommonStockUponNetExerciseOfWarrants	0	USD
CY2015Q2	rvnc	Gain Loss On Settlement In Exchange Of Preferred Stock Warrants GainLossOnSettlementInExchangeOfPreferredStockWarrants	0	USD
CY2012	rvnc	Gain Losson Derivative Instruments Contract Net Pretax GainLossonDerivativeInstrumentsContractNetPretax	47000	USD
CY2014Q2	rvnc	Gain Losson Derivative Instruments Contract Net Pretax GainLossonDerivativeInstrumentsContractNetPretax	-76000	USD
	rvnc	Gain Losson Derivative Instruments Contract Net Pretax GainLossonDerivativeInstrumentsContractNetPretax	-493000	USD
CY2015Q2	rvnc	Gain Losson Derivative Instruments Contract Net Pretax GainLossonDerivativeInstrumentsContractNetPretax	89000	USD
	rvnc	Gain Losson Derivative Instruments Contract Net Pretax GainLossonDerivativeInstrumentsContractNetPretax	47000	USD
CY2014Q2	rvnc	Interest Expense Capitalized InterestExpenseCapitalized	180000	USD
	rvnc	Interest Expense Capitalized InterestExpenseCapitalized	411000	USD
CY2015Q2	rvnc	Interest Expense Capitalized InterestExpenseCapitalized	0	USD
	rvnc	Interest Expense Capitalized InterestExpenseCapitalized	0	USD
CY2014Q2	rvnc	Interest Expense Convertible Notes InterestExpenseConvertibleNotes	0	USD
	rvnc	Interest Expense Convertible Notes InterestExpenseConvertibleNotes	1250000	USD
CY2015Q2	rvnc	Interest Expense Convertible Notes InterestExpenseConvertibleNotes	0	USD
	rvnc	Interest Expense Convertible Notes InterestExpenseConvertibleNotes	0	USD
CY2014Q2	rvnc	Interest Expense Debt Issuance Costs InterestExpenseDebtIssuanceCosts	48000	USD
	rvnc	Interest Expense Debt Issuance Costs InterestExpenseDebtIssuanceCosts	100000	USD
CY2015Q2	rvnc	Interest Expense Debt Issuance Costs InterestExpenseDebtIssuanceCosts	0	USD
	rvnc	Interest Expense Debt Issuance Costs InterestExpenseDebtIssuanceCosts	39000	USD
CY2014Q2	rvnc	Interest Expense Warrantand Derivative Related Debt Discounts InterestExpenseWarrantandDerivativeRelatedDebtDiscounts	75000	USD
	rvnc	Non Cash Deferred Followon Public Offering Costs NonCashDeferredFollowonPublicOfferingCosts	546000	USD
	rvnc	Non Cash Deferred Followon Public Offering Costs NonCashDeferredFollowonPublicOfferingCosts	0	USD
	rvnc	Noncash Deferred Initial Public Offering Costs NoncashDeferredInitialPublicOfferingCosts	4028000	USD
	rvnc	Noncash Deferred Initial Public Offering Costs NoncashDeferredInitialPublicOfferingCosts	0	USD
CY2014Q2	rvnc	Noncash Interest Expense NoncashInterestExpense	-57000	USD
	rvnc	Noncash Interest Expense NoncashInterestExpense	9412000	USD
CY2015Q2	rvnc	Noncash Interest Expense NoncashInterestExpense	89000	USD
	rvnc	Noncash Interest Expense NoncashInterestExpense	144000	USD
	rvnc	Revaluation Of Convertible Redeemable Preferred Stock Warrants RevaluationOfConvertibleRedeemablePreferredStockWarrants	210000	USD
	rvnc	Revaluation Of Convertible Redeemable Preferred Stock Warrants RevaluationOfConvertibleRedeemablePreferredStockWarrants	0	USD
	rvnc	Terminationof Stock Option Repurchase Right Noncash TerminationofStockOptionRepurchaseRightNoncash	58000	USD
	rvnc	Terminationof Stock Option Repurchase Right Noncash TerminationofStockOptionRepurchaseRightNoncash	0	USD
CY2015Q2	rvnc	Working Capital Surplus WorkingCapitalSurplus	127100000	USD
	rvnc	Writeoffof Fixed Assets WriteoffofFixedAssets	0	USD
	rvnc	Writeoffof Fixed Assets WriteoffofFixedAssets	28000	USD
CY2014Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3149000	USD
CY2015Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	2211000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	0	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-128000	USD
CY2014Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4145000	USD
CY2014Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	0	USD
CY2015Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-12000	USD
CY2015Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5040000	USD
CY2014Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	435142000	USD
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	0	USD
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	1095000	USD
CY2015Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	439833000	USD
CY2014Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1499000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2327000	USD
CY2015Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2407000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4724000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1122000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	5000	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	99000	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	39000	USD
CY2014Q4	us-gaap	Assets Assets	192469000	USD
CY2015Q2	us-gaap	Assets Assets	171216000	USD
CY2014Q4	us-gaap	Assets Current AssetsCurrent	172731000	USD
CY2015Q2	us-gaap	Assets Current AssetsCurrent	137256000	USD
CY2014Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	166038000	USD
CY2015Q2	us-gaap	Available For Sale Securities AvailableForSaleSecurities	143595000	USD
CY2014Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2015Q2	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	2000	USD
CY2014Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	USD
CY2015Q2	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	14000	USD
CY2014Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	166038000	USD
CY2015Q2	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	143607000	USD
CY2012	us-gaap	Available For Sale Securities Gross Unrealized Loss AvailableForSaleSecuritiesGrossUnrealizedLoss	12000	USD
CY2014Q2	us-gaap	Available For Sale Securities Gross Unrealized Loss AvailableForSaleSecuritiesGrossUnrealizedLoss	0	USD
	us-gaap	Available For Sale Securities Gross Unrealized Loss AvailableForSaleSecuritiesGrossUnrealizedLoss	0	USD
CY2015Q2	us-gaap	Available For Sale Securities Gross Unrealized Loss AvailableForSaleSecuritiesGrossUnrealizedLoss	12000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3914000	USD
CY2014Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	203308000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	171032000	USD
CY2015Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	96417000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	199394000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-74615000	USD
CY2014Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	95000000	shares
CY2015Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	95000000	shares
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	23774465	shares
CY2015Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	23945936	shares
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	23774465	shares
CY2015Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	23945936	shares
CY2014Q4	us-gaap	Common Stock Value CommonStockValue	24000	USD
CY2015Q2	us-gaap	Common Stock Value CommonStockValue	24000	USD
CY2012	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-32219000	USD
CY2014Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-13302000	USD
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	0	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-34728000	USD
CY2015Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-16817000	USD
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	123982000	USD
	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	26206000	USD
	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	0	USD
CY2014Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	3725000	USD
CY2015Q2	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	3751000	USD
	us-gaap	Depreciation Depreciation	1019000	USD
	us-gaap	Depreciation Depreciation	1075000	USD
CY2014Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	1541000	USD
CY2015Q2	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	1494000	USD
CY2012	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.37
CY2014Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.69
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.26
CY2015Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.71
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.37
CY2012	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.37
CY2014Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.69
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.26
CY2015Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.71
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.37
CY2012	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
CY2014Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	2151000	USD
CY2015Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
CY2014Q2	us-gaap	Financing Interest Expense FinancingInterestExpense	0	USD
	us-gaap	Financing Interest Expense FinancingInterestExpense	0	USD
CY2015Q2	us-gaap	Financing Interest Expense FinancingInterestExpense	89000	USD
	us-gaap	Financing Interest Expense FinancingInterestExpense	100000	USD
CY2012	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	0	USD
CY2014Q2	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	0	USD
	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	4032000	USD
CY2015Q2	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	0	USD
	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	0	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-29000	USD
CY2014Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-8331000	USD
CY2015Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-4084000	USD
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-938000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	1633000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	2234000	USD
	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	-7073000	USD
	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	0	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	1055000	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	345000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1340000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	412000	USD
	us-gaap	Increase Decrease In Prepaid Rent IncreaseDecreaseInPrepaidRent	-451000	USD
	us-gaap	Interest Expense Debt InterestExpenseDebt	271000	USD
	us-gaap	Increase Decrease In Prepaid Rent IncreaseDecreaseInPrepaidRent	-103000	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	-75000	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	-75000	USD
CY2012	us-gaap	Interest Expense InterestExpense	444000	USD
CY2014Q2	us-gaap	Interest Expense InterestExpense	267000	USD
	us-gaap	Interest Expense InterestExpense	10108000	USD
CY2015Q2	us-gaap	Interest Expense InterestExpense	279000	USD
	us-gaap	Interest Expense InterestExpense	444000	USD
	us-gaap	Interest Expense Debt InterestExpenseDebt	0	USD
CY2014Q2	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	324000	USD
	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	696000	USD
CY2015Q2	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	190000	USD
	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	300000	USD
	us-gaap	Interest Paid InterestPaid	696000	USD
	us-gaap	Interest Paid InterestPaid	300000	USD
CY2012	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	76000	USD
CY2014Q2	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	1000	USD
	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	4000	USD
CY2015Q2	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	49000	USD
CY2014Q1	us-gaap	Lessee Leasing Arrangements Operating Leases Renewal Term LesseeLeasingArrangementsOperatingLeasesRenewalTerm	P36M
CY2014Q4	us-gaap	Liabilities Liabilities	16100000	USD
CY2015Q2	us-gaap	Liabilities Liabilities	22375000	USD
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	192469000	USD
CY2015Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	171216000	USD
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	10236000	USD
CY2015Q2	us-gaap	Liabilities Current LiabilitiesCurrent	10157000	USD
CY2014Q4	us-gaap	Long Term Investments LongTermInvestments	0	USD
CY2015Q2	us-gaap	Long Term Investments LongTermInvestments	14052000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	235997000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	6190000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3343000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-55293000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-33260000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-25512000	USD
CY2012	us-gaap	Net Income Loss NetIncomeLoss	-32207000	USD
CY2014Q2	us-gaap	Net Income Loss NetIncomeLoss	-13302000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-34728000	USD
CY2015Q2	us-gaap	Net Income Loss NetIncomeLoss	-16805000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-32207000	USD
CY2012	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-32207000	USD
CY2014Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-13302000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-34728000	USD
CY2015Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-16805000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-32207000	USD
CY2012	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-32207000	USD
CY2014Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-13302000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-34728000	USD
CY2015Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-16805000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-32207000	USD
	us-gaap	Noncash Or Part Noncash Acquisition Net Nonmonetary Assets Acquired Liabilities Assumed1 NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1	1484000	USD
	us-gaap	Noncash Or Part Noncash Acquisition Net Nonmonetary Assets Acquired Liabilities Assumed1 NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1	20000	USD
	us-gaap	Notes Assumed1 NotesAssumed1	1050000	USD
	us-gaap	Notes Assumed1 NotesAssumed1	0	USD
CY2014Q4	us-gaap	Notes Payable Current NotesPayableCurrent	2635000	USD
CY2015Q2	us-gaap	Notes Payable Current NotesPayableCurrent	0	USD
CY2012	us-gaap	Operating Expenses OperatingExpenses	31913000	USD
CY2014Q2	us-gaap	Operating Expenses OperatingExpenses	12967000	USD
	us-gaap	Operating Expenses OperatingExpenses	24611000	USD
CY2015Q2	us-gaap	Operating Expenses OperatingExpenses	16663000	USD
CY2012	us-gaap	Operating Income Loss OperatingIncomeLoss	-31763000	USD
CY2014Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-12892000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-24378000	USD
CY2015Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-16588000	USD
CY2015Q2	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	51086000	USD
CY2015Q2	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	2538000	USD
CY2015Q2	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	5578000	USD
CY2015Q2	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	5394000	USD
CY2015Q2	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	5222000	USD
CY2015Q2	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	32354000	USD
CY2014Q2	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	1300000	USD
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	2600000	USD
CY2015Q2	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	1300000	USD
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	2600000	USD
	us-gaap	Operations Commenced Date1 OperationsCommencedDate1	2002-06-30
CY2014Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	29000	USD
CY2015Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	374000	USD
	us-gaap	Other Comprehensive Income Loss Before Reclassifications Before Tax OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax	-12000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-12000	USD
CY2012	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-123000	USD
CY2014Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-68000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-68000	USD
CY2015Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-76000	USD
	us-gaap	Payments For Repurchase Of Warrants PaymentsForRepurchaseOfWarrants	1438000	USD
	us-gaap	Payments For Repurchase Of Warrants PaymentsForRepurchaseOfWarrants	0	USD
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	0	USD
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	620000	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	0	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	53076000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3418000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2292000	USD
CY2014Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1624000	USD
CY2015Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1920000	USD
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	102672000	USD
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	131882000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	6750000	USD
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	303000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	587000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	19274000	USD
CY2015Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	19134000	USD
CY2015Q2	us-gaap	Purchase Obligation PurchaseObligation	20100000	USD
	us-gaap	Reclassification From Accumulated Other Comprehensive Income Current Period Before Tax ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax	0	USD
	us-gaap	Repayments Of Long Term Debt And Capital Securities RepaymentsOfLongTermDebtAndCapitalSecurities	66000	USD
	us-gaap	Repayments Of Long Term Debt And Capital Securities RepaymentsOfLongTermDebtAndCapitalSecurities	956000	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	4106000	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	2652000	USD
CY2012	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	19557000	USD
CY2014Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8110000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	15661000	USD
CY2015Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10303000	USD
CY2014Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	75000	USD
CY2015Q2	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	35000	USD
CY2014Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	435000	USD
CY2015Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	400000	USD
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-258797000	USD
CY2015Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-291004000	USD
CY2012	us-gaap	Revenues Revenues	150000	USD
CY2014Q2	us-gaap	Revenues Revenues	75000	USD
	us-gaap	Revenues Revenues	233000	USD
CY2015Q2	us-gaap	Revenues Revenues	75000	USD
	us-gaap	Sale Leaseback Transaction Net Proceeds Financing Activities SaleLeasebackTransactionNetProceedsFinancingActivities	0	USD
	us-gaap	Sale Leaseback Transaction Net Proceeds Financing Activities SaleLeasebackTransactionNetProceedsFinancingActivities	9831000	USD
CY2012	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	12356000	USD
CY2014Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4857000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	8950000	USD
CY2015Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	6360000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	2327000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	4724000	USD
CY2014Q4	us-gaap	Short Term Investments ShortTermInvestments	0	USD
CY2015Q2	us-gaap	Short Term Investments ShortTermInvestments	38884000	USD
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	176369000	USD
CY2015Q2	us-gaap	Stockholders Equity StockholdersEquity	148841000	USD
CY2012	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	23560133	shares
CY2014Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	19380934	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	15361215	shares
CY2015Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	23584910	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	23560133	shares
CY2012	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	23560133	shares
CY2014Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	19380934	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	15361215	shares
CY2015Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	23584910	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	23560133	shares
	us-gaap	Loss Contingency Disclosures LossContingencyDisclosures	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Medicis Settlement</font></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In </font><font style="font-family:inherit;font-size:10pt;">October 2012</font><font style="font-family:inherit;font-size:10pt;">, the Company entered into a settlement and termination agreement with Medicis Pharmaceutical Corporation, or Medicis. Medicis was subsequently acquired by Valeant Pharmaceuticals International, Inc. in December 2012. The terms of the settlement provided for the reacquisition of the rights related to all territories of RT001 and RT002 from Medicis and for consideration payable by the Company to Medicis of up to </font><font style="font-family:inherit;font-size:10pt;">$25.0 million</font><font style="font-family:inherit;font-size:10pt;">, comprised of (i) an upfront payment of </font><font style="font-family:inherit;font-size:10pt;">$7.0 million</font><font style="font-family:inherit;font-size:10pt;">, which was paid in 2012, (ii) a Proceeds Sharing Arrangement Payment of </font><font style="font-family:inherit;font-size:10pt;">$14.0 million</font><font style="font-family:inherit;font-size:10pt;"> due upon specified capital raising achievements by the Company, of which </font><font style="font-family:inherit;font-size:10pt;">$6.9 million</font><font style="font-family:inherit;font-size:10pt;"> was paid in 2013 and the remaining </font><font style="font-family:inherit;font-size:10pt;">$7.1 million</font><font style="font-family:inherit;font-size:10pt;"> was paid in 2014, and (iii) </font><font style="font-family:inherit;font-size:10pt;">$4.0 million</font><font style="font-family:inherit;font-size:10pt;"> to be paid upon the achievement of regulatory approval for RT001 or RT002 by the Company, or Product Approval Payment. </font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">June 30, 2015</font><font style="font-family:inherit;font-size:10pt;">, the Company determined the fair value of its liability for the Product Approval Payment was </font><font style="font-family:inherit;font-size:10pt;">$1.5 million</font><font style="font-family:inherit;font-size:10pt;">, which was measured by assuming a term of </font><font style="font-family:inherit;font-size:10pt;">4</font><font style="font-family:inherit;font-size:10pt;"> years, a risk-free rate of </font><font style="font-family:inherit;font-size:10pt;">1.3%</font><font style="font-family:inherit;font-size:10pt;"> and a credit risk adjustment of </font><font style="font-family:inherit;font-size:10pt;">6.3%</font><font style="font-family:inherit;font-size:10pt;">. The Company’s assumption for the expected term is based on an expected Biologics License Application, or BLA, approval in 2019. The Company did not make any payments under the Product Approval Payment during the </font><font style="font-family:inherit;font-size:10pt;">six months ended June 30, 2015</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the amounts reported in the Condensed Consolidated Financial Statements and accompanying notes. Such management estimates include the fair value of common stock, stock-based compensation, fair value of convertible preferred stock and warrants, fair value of derivatives, and the valuation of deferred tax assets. The Company bases its estimates on historical experience and also on assumptions that it believes are reasonable, however, actual results could significantly differ from those estimates</font></div></div>

Files In Submission

Name	View Source	Status
0001628280-15-006314-index-headers.html	Edgar Link	pending
0001628280-15-006314-index.html	Edgar Link	pending
0001628280-15-006314.txt	Edgar Link	pending
0001628280-15-006314-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
rvnc-20150630.xml	Edgar Link	completed
rvnc-20150630.xsd	Edgar Link	pending
rvnc-20150630_cal.xml	Edgar Link	unprocessable
rvnc-20150630_def.xml	Edgar Link	unprocessable
rvnc-20150630_lab.xml	Edgar Link	unprocessable
rvnc-20150630_pre.xml	Edgar Link	unprocessable
rvnc-exhibit102.htm	Edgar Link	pending
rvnc-exhibit311.htm	Edgar Link	pending
rvnc-exhibit312.htm	Edgar Link	pending
rvnc-exhibit321.htm	Edgar Link	pending
rvnc-exhibit322.htm	Edgar Link	pending
rvnc06301510q.htm	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RVNC
Revance Therapeutics, Inc. Stock $rvnc

2015 Q2 Form 10-Q Financial Statement

#000162828015006314 Filed on August 07, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RVNC Revance Therapeutics, Inc. Stock $rvnc

2015 Q2 Form 10-Q Financial Statement

#000162828015006314 Filed on August 07, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RVNC
Revance Therapeutics, Inc. Stock $rvnc